Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Recruiting 2Unknown 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Endocrine 3

Conditions

Thyroid Neoplasms 6Thyroid Cancer, Papillary 3Adenocarcinoma, Follicular 3Recombinant Human Thyroid Stimulating Hormone 1Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation 1Low Risk Differentiated Thyroid Cancer 1Heterotaxy Syndrome 1Head and Neck Neoplasms 1DTC - Differentiated Thyroid Cancer 1

Interventions

Iodine-131 5lenvatinib 3X-Rays 3Thyrotropin Alfa 3Magnetic Resonance Spectroscopy 3trametinib 2dabrafenib 2Sunitinib 2Specimen Handling 2Interviews as Topic 2vandetanib 1tremelimumab 1spartalizumab 1selpercatinib 1pembrolizumab 1pazopanib 1durvalumab 1cobimetinib 1cabozantinib 1Vemurafenib 1Thyrotropin 1Thalidomide 1Surgical Procedures, Operative 1Sorafenib 1Sodium Iodide 1Semaxinib 1Photons 1Photochemotherapy 1Phantoms, Imaging 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Adenocarcinoma, Follicular × Thyrotropin Alfa × Clear all
NCT06440850 2026-02-02

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2 Recruiting
21 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT05668962 2024-12-12

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Massachusetts General Hospital

Phase 2 Recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT00415233 2023-12-19

HiLo

University College, London

Phase 3 Unknown
438 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Head and Neck Neoplasms, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡